152 related articles for article (PubMed ID: 2106529)
21. Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery.
Damjanović SS; Petakov MS; Raicević S; Micić D; Marinković J; Dieguez C; Casanueva FF; Popović V
J Clin Endocrinol Metab; 2000 Jan; 85(1):147-54. PubMed ID: 10634378
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of suppression of growth hormone levels following a 75g oral glucose tolerance test.
Nazaimoon WM; Ng ML; Satgunasingam N; Khalid BA
Med J Malaysia; 1992 Jun; 47(2):103-9. PubMed ID: 1494329
[TBL] [Abstract][Full Text] [Related]
23. Low serum IGF-I/GH ratio is associated with abnormal glucose tolerance in acromegaly.
Fukuoka H; Takahashi Y; Iida K; Kudo T; Nishizawa H; Imanaka M; Takeno R; Iguchi G; Takahashi K; Okimura Y; Kaji H; Chihara K
Horm Res; 2008; 69(3):165-71. PubMed ID: 18219220
[TBL] [Abstract][Full Text] [Related]
24. Homocysteine levels in acromegaly patients.
Hekimsoy Z; Ozmen B; Ulusoy S
Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
[TBL] [Abstract][Full Text] [Related]
25. Effects of growth hormone-releasing factor on growth hormone secretion in acromegaly.
Gelato MC; Merriam GR; Vance ML; Goldman JA; Webb C; Evans WS; Rock J; Oldfield EH; Molitch ME; Rivier J
J Clin Endocrinol Metab; 1985 Feb; 60(2):251-7. PubMed ID: 3917454
[TBL] [Abstract][Full Text] [Related]
26. Neurosurgery restores late GH rise after glucose-induced suppression in cured acromegalics.
Attanasio R; Oppizzi G; Lodrini S; Dallabonzana D; Barausse M; Orlandi P; DaRe N; Cozzi R
Eur J Endocrinol; 1999 Jan; 140(1):23-8. PubMed ID: 10037247
[TBL] [Abstract][Full Text] [Related]
27. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.
Serri O; Beauregard C; Hardy J
J Clin Endocrinol Metab; 2004 Feb; 89(2):658-61. PubMed ID: 14764777
[TBL] [Abstract][Full Text] [Related]
28. Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly.
Shibasaki T; Hotta M; Masuda A; Imaki T; Obara N; Hizuka N; Takano K; Wakabayashi I; Demura H; Ling N
J Clin Endocrinol Metab; 1986 Jul; 63(1):167-73. PubMed ID: 2872226
[TBL] [Abstract][Full Text] [Related]
29. Effect of oral glucose administration on plasma growth hormone-releasing hormone (GHRH)-like immunoreactivity levels in normal subjects and patients with idiopathic GH deficiency: evidence that GHRH is released not only from the hypothalamus but also from extrahypothalamic tissue.
Kashio Y; Chihara K; Kita T; Okimura Y; Sato M; Kadowaki S; Fujita T
J Clin Endocrinol Metab; 1987 Jan; 64(1):92-7. PubMed ID: 3097059
[TBL] [Abstract][Full Text] [Related]
30. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
[TBL] [Abstract][Full Text] [Related]
31. Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly.
Kim EH; Oh MC; Lee EJ; Kim SH
Neurosurgery; 2012 May; 70(5):1106-13; discussion 1113. PubMed ID: 22067418
[TBL] [Abstract][Full Text] [Related]
32. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.
Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Florimonte L; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1999 Jan; 84(1):17-23. PubMed ID: 9920056
[TBL] [Abstract][Full Text] [Related]
33. Growth hormone inhibitory and stimulatory actions of L-dopa in patients with acromegaly.
Hanew K; Sasaki A; Sato S; Goh M; Yoshinaga K
J Clin Endocrinol Metab; 1987 Feb; 64(2):255-60. PubMed ID: 3793848
[TBL] [Abstract][Full Text] [Related]
34. Urinary growth hormone (GH) measurements are useful for evaluating endogenous GH secretion.
Sukegawa I; Hizuka N; Takano K; Asakawa K; Horikawa R; Hashida S; Ishikawa E; Mohri Z; Murakami Y; Shizume K
J Clin Endocrinol Metab; 1988 Jun; 66(6):1119-23. PubMed ID: 3286672
[TBL] [Abstract][Full Text] [Related]
35. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
36. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
[TBL] [Abstract][Full Text] [Related]
37. Stimulation of growth hormone by vasoactive intestinal polypeptide in acromegaly.
Chihara K; Kaji H; Minamitani N; Kodama H; Kita T; Goto B; Chiba T; Coy DH; Fujita T
J Clin Endocrinol Metab; 1984 Jan; 58(1):81-6. PubMed ID: 6417157
[TBL] [Abstract][Full Text] [Related]
38. Value of growth hormone dynamics and somatomedin C (insulin-like growth factor I) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly.
Arafah BM; Rosenzweig JL; Fenstermaker R; Salazar R; McBride CE; Selman W
J Lab Clin Med; 1987 Mar; 109(3):346-54. PubMed ID: 3102658
[TBL] [Abstract][Full Text] [Related]
39. [Clinical application of a sensitive immunoradiometric assay for human growth hormone].
Shimatsu A; Hattori N; Tanoh T; Assadian H; Imura H
Nihon Naibunpi Gakkai Zasshi; 1990 Jul; 66(7):715-25. PubMed ID: 2118864
[TBL] [Abstract][Full Text] [Related]
40. Effect of CB-154 therapy on the glucose tolerance, IRI and GH response to glucose administration in acromegaly.
Demura R; Yamaguchi H; Demura H; Shizume K
Endocrinol Jpn; 1978 Aug; 25(4):355-9. PubMed ID: 710371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
